Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 578
Filtrar
1.
Sci Rep ; 14(1): 14344, 2024 06 21.
Artículo en Inglés | MEDLINE | ID: mdl-38906933

RESUMEN

Sysmex DI-60 enumerates and classifies leukocytes. Limited research has evaluated the performance of Sysmex DI-60 in abnormal samples, and most focused on leukopenic samples. We evaluate the efficacy of DI-60 in determining white blood cell (WBC) differentials in normal and abnormal samples in different WBC count. Peripheral blood smears (n = 166) were categorised into normal control and disease groups, and further divided into moderate and severe leucocytosis, mild leucocytosis, normal, mild leukopenia, and moderate and severe leukopenia groups based on WBC count. DI-60 preclassification and verification and manual counting results were assessed using Bland-Altman and Passing-Bablok regression analyses. The Kappa test compared the concordance in the abnormal cell detection between DI-60 and manual counting. DI-60 exhibited notable overall sensitivity and specificity for all cells, except basophils. The correlation between the DI-60 preclassification and manual counting was high for segmented neutrophils, band neutrophils, lymphocytes, and blasts, and improved for all cell classes after verification. The mean difference between DI-60 and manual counting for all cell classes was significantly high in moderate and severe leucocytosis (WBC > 30.0 × 109/L) and moderate and severe leukopenia (WBC < 1.5 × 109/L) groups. For blast cells, immature granulocytes, and atypical lymphocytes, the DI-60 verification results were similar to the manual counting results. Plasma cells showed poor agreement. In conclusion, DI-60 demonstrates consistent and reliable analysis of WBC differentials within the range of 1.5-30.0 × 109. Manual counting was indispensable in examining moderate and severe leucocytosis samples, moderate and severe leukopenia samples, and in enumerating of monocytes and plasma cells.


Asunto(s)
Leucocitos , Leucopenia , Humanos , Recuento de Leucocitos/métodos , Recuento de Leucocitos/instrumentación , Leucocitos/citología , Leucocitos/patología , Leucopenia/diagnóstico , Leucopenia/sangre , Leucopenia/patología , Leucocitosis/sangre , Leucocitosis/diagnóstico , Leucocitosis/patología , Sensibilidad y Especificidad , Femenino , Masculino , Neutrófilos/citología , Neutrófilos/patología , Persona de Mediana Edad
2.
Transfusion ; 64(6): 986-997, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38661229

RESUMEN

BACKGROUND: Laboratory results are frequently abnormal in pregnant mothers. Abnormalities usually relate to pregnancy or associated complications. Hematological abnormalities and age in pregnancy may increase the likelihood for transfusion and mortality. STUDY DESIGN AND METHODS: Hematological profiles and transfusion history of pregnant mothers presenting to a tertiary hospital, were evaluated over 2 years. Age, anemia, leukocytosis and thrombocytopenia were assessed for transfusion likelihood. Iron deficiency and coagulation were assessed in transfused patients. Anemia, leukocytosis, thrombocytopenia, human immunodeficiency virus (HIV) and transfusion were assessed for mortality likelihood. RESULTS: There were 12,889 pregnant mothers included. Mothers <19-years-old had the highest prevalence of anemia (31.5%) and proportion of transfusions (19%). The transfusion likelihood was increased in mothers with anemia (odds ratios [OR] = 6.41; confidence intervals at 95% [95% CI] 5.46-7.71), leukocytosis (OR = 2.35; 95% CI 2.00-2.76) or thrombocytopenia (OR = 2.71; 95% CI 2.21-3.33). Mothers with prolonged prothrombin times received twice as many blood products as their normal counterparts (p = .03) and those with iron deficiency anemia five times more blood products (p < .001). Increased likelihood for mortality was seen in patients with anemia (OR = 4.15, 95% CI 2.03-8.49), leukocytosis (OR = 2.68; 95% CI 1.19-6.04) and those receiving blood transfusion (OR = 3.6, 95% CI 1.75-7.47). DISCUSSION: Adolescence, anemia, leukocytosis and thrombocytopenia expose mothers to a high risk for transfusion and/or mortality. These risk factors should promptly trigger management and referral of patients. Presenting hematological profiles are strong predictors of maternal outcome and transfusion risk.


Asunto(s)
Transfusión Sanguínea , Complicaciones Hematológicas del Embarazo , Centros de Atención Terciaria , Humanos , Femenino , Embarazo , Adulto , Sudáfrica/epidemiología , Complicaciones Hematológicas del Embarazo/sangre , Complicaciones Hematológicas del Embarazo/mortalidad , Complicaciones Hematológicas del Embarazo/terapia , Complicaciones Hematológicas del Embarazo/epidemiología , Trombocitopenia/sangre , Trombocitopenia/mortalidad , Trombocitopenia/etiología , Anemia/sangre , Anemia/mortalidad , Anemia/etiología , Anemia/epidemiología , Adulto Joven , Adolescente , Factores de Riesgo , Leucocitosis/mortalidad , Leucocitosis/sangre
5.
Rev. Soc. Bras. Clín. Méd ; 20(2): 108-112, 2022.
Artículo en Portugués | LILACS | ID: biblio-1428751

RESUMEN

A Síndrome de DRESS (do inglês, Drug Rash with Eosinophilia and Systemic Symptoms) é uma patologia rara que consiste em uma severa reação medicamentosa mediada por células T. O presente relato de caso retrata uma paciente do sexo feminino, 59 anos, que apresentou icterícia, febre não termometrada, acolia, colúria, mialgia, placas hipercrômicas e lesões pruriginosas. Referiu uso recente de alopurinol, paracetamol e nimesulida, apresentando melhora importante e espontânea após a suspensão das medicações. A extensão do tempo de exposição ao medicamento agressor ocasiona um maior período de internação e risco de mortalidade. Além disso, os dados restritos sobre a Síndrome de DRESS impõe desafios ao seu diagnóstico. Sendo assim, este estudo busca destacar a importância do diagnóstico clínico precoce, a suspensão do medicamento agressor e a instituição da terapêutica adequada para um prognóstico favorável


The Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is a rare pathology that consists of a severe drug reaction mediated by T cells. The present case report depicts a female patient, 59 years old, who presented jaundice, non thermometered fever, acholia, choluria, myalgia, hyperchromic plaques and pruritic lesions. She mentioned recent use of allopurinol, paracetamol and nimesulide, showing significant and spontaneous improvement after discontinuation of medications. The extension of time of exposure to the offending drug causes a longer period of hospitalization and risk of mortality. In addition, the restricted data on DRESS Syndrome poses challenges to its diagnosis. Therefore, this study seeks to highlight the importance of early clinical diagnosis, suspension of the offending drug and the institution of appropriate therapy for a favorable prognosis


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Enfermedades de la Piel/inducido químicamente , Alopurinol/efectos adversos , Supresores de la Gota/efectos adversos , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Fallo Hepático Agudo/inducido químicamente , Eosinofilia/sangre , Exantema/inducido químicamente , Síndrome de Hipersensibilidad a Medicamentos/sangre , Leucocitosis/sangre
6.
Int J Lab Hematol ; 43(6): 1309-1318, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34523805

RESUMEN

INTRODUCTION: Developing prognostic markers can be useful for clinical decision-making. Peripheral blood (PB) examination is simple and basic that can be performed in any facility. We aimed to investigate whether PB examination can predict prognosis in coronavirus disease (COVID-19). METHODS: Complete blood count (CBC) and PB cell morphology were examined in 38 healthy controls (HCs) and 40 patients with COVID-19. Patients with COVID-19, including 26 mild and 14 severe cases, were hospitalized in Juntendo University Hospital (Tokyo, Japan) between April 1 and August 6, 2020. PB examinations were performed using Sysmex XN-3000 automated hematology analyzer and Sysmex DI-60 employing the convolutional neural network-based automatic image-recognition system. RESULTS: Compared with mild cases, severe cases showed a significantly higher incidence of anemia, lymphopenia, and leukocytosis (P < .001). Granular lymphocyte counts were normal or higher in mild cases and persistently decreased in fatal cases. Temporary increase in granular lymphocytes was associated with survival of patients with severe infection. Red cell distribution width was significantly higher in severe cases than in mild cases (P < .001). Neutrophil dysplasia was consistently observed in COVID-19 cases, but not in HCs. Levels of giant neutrophils and toxic granulation/Döhle bodies were increased in severe cases. CONCLUSION: Basic PB examination can be useful to predict the prognosis of COVID-19, by detecting SARS-CoV-2 infection-induced multi-lineage changes in blood cell counts and morphological anomalies. These changes were dynamically correlated with disease severity and may be associated with disruption of hematopoiesis and the immunological system due to bone marrow stress in severe infection.


Asunto(s)
Recuento de Células Sanguíneas , COVID-19/sangre , Leucocitosis/etiología , Linfocitos/ultraestructura , Linfopenia/etiología , Neutrófilos/ultraestructura , SARS-CoV-2 , Anciano , Anemia/sangre , Anemia/etiología , Recuento de Células Sanguíneas/instrumentación , Recuento de Células Sanguíneas/métodos , COVID-19/mortalidad , Forma de la Célula , Gránulos Citoplasmáticos/ultraestructura , Índices de Eritrocitos , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Leucocitosis/sangre , Recuento de Linfocitos , Linfopenia/sangre , Masculino , Persona de Mediana Edad , Redes Neurales de la Computación , Pronóstico , Índice de Severidad de la Enfermedad
7.
J Vasc Surg ; 74(6): 1843-1852.e3, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34174377

RESUMEN

OBJECTIVES: Elevated white blood cell count (WBC) can be predictive of adverse outcomes following vascular interventions, but the association has not established using multi-institutional data. We evaluated the predictive value of preoperative WBC after endovascular aneurysm repair (EVAR) for nonruptured abdominal aortic aneurysms (AAAs) in a nationally representative surgical database. METHODS: Patients with nonruptured AAA undergoing EVAR were identified in the vascular-targeted National Surgical Quality Improvement Program (NSQIP) database. Baseline characteristics were compared between patients with WBC <10 K/µL and WBC ≥10 K/µL. Multivariable logistic regression analyses were performed to assess the odds of outcomes. The primary outcome was 30-day mortality. Multiple secondary outcomes including length of stay (LOS) > 1 week, 30-day readmission, lower extremity (LE) ischemia, ischemic colitis, myocardial infarction, and others were assessed based on WBC and patient sex. RESULTS: A total of 10,955 patients were included, with a mean WBC 7.7 ± 2.7 K/µL. Patients with WBC ≥10 K/µL were younger (71.8 ± 9.5 years vs 74.1 ± 8.7 years; P < .001) and were more likely to be diabetic, on steroids, smokers, functionally dependent, and presenting emergently (all P ≤ .009). Aneurysm diameter was larger in patients with WBC ≥10 K/µL (5.9 ± 1.5 cm vs 5.7 ± 1.5 cm; P < .001). Patients with WBC ≥10 K/µL had more mortality (2.4% vs 1.3%), LOS >1 week (13.5% vs 6.7%), 30-day readmissions (9.8% vs 7.3%), LE ischemia (2.3% vs 1.4%), ischemic colitis (1.2% vs 0.5%), and myocardial infarction (2.0% vs 1.1%) (all P ≤ .008). Female patients with WBC ≥10 K/µL, compared with male patients with WBC ≥10 K/µL, had more adverse events, including mortality, LOS >1 week, 30-day readmission, and LE ischemia (all P ≤ .025). With each incremental increase in WBC by 1 K/µL, the adjusted odds ratio of adverse outcomes for all patient was higher (mortality: 1.05; 95% confidence interval [CI], 1.00-1.10; readmission: 1.03; 95% CI, 1.00-1.06; LOS >1 week: 1.08; 95% CI, 1.05-1.10; and ischemic colitis: 1.11; 95% CI, 1.05-1.16; all P < .05). The effect was more pronounced in female patients and was statistically significant. CONCLUSIONS: WBC is a predictor of adverse outcomes in patients undergoing EVAR for nonruptured AAA. After adjusting for associated risk factors, the effect of increasing WBC was more prominent for female patients. Preoperative WBC should be used as a prognostic factor to predict adverse outcomes among patients undergoing EVAR.


Asunto(s)
Aneurisma de la Aorta Abdominal/cirugía , Implantación de Prótesis Vascular/efectos adversos , Procedimientos Endovasculares/efectos adversos , Leucocitos , Leucocitosis/diagnóstico , Complicaciones Posoperatorias/etiología , Anciano , Anciano de 80 o más Años , Aneurisma de la Aorta Abdominal/complicaciones , Aneurisma de la Aorta Abdominal/diagnóstico por imagen , Aneurisma de la Aorta Abdominal/mortalidad , Implantación de Prótesis Vascular/mortalidad , Bases de Datos Factuales , Procedimientos Endovasculares/mortalidad , Femenino , Humanos , Recuento de Leucocitos , Leucocitosis/sangre , Leucocitosis/complicaciones , Leucocitosis/mortalidad , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/mortalidad , Complicaciones Posoperatorias/terapia , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores Sexuales , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos
9.
Diabetes Metab Syndr ; 15(2): 535-541, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33711574

RESUMEN

BACKGROUND AND AIMS: Corona virus disease 2019 (COVID-19) has been an extremely difficult pandemic to contain and it has affected more than 148 countries worldwide. The main aim of this systematic review is to provide a comprehensive summary of clinical and laboratory parameters that are associated with and indicative of increased severity among COVID-19 patients. MATERIAL AND METHODS: All the available data from high-quality research articles relevant to the epidemiology, demographics, trends in hospitalization and outcomes, clinical signs and symptoms, diagnostic methods and treatment methods of COVID-19 were retrieved and evaluated for inclusion. RESULTS: As per our review, the mean age of patients in the severe group was 59.3 years compared to 46.5 years in non severe group. COVID-19 was more severe among men than women. Clinical presentation was variable among different studies. and dyspnea was the factor indicating severe disease. Laboratory parameters associated with increased severity were lymphopenia <0.8 × 109/L, thrombocytopenia 100 × 109/L, leucocytosis TC > 11 × 109/L, procalcitonin >0.5 ng/mL, d dimer >2 mcg/mL, aspartate transaminase elevation >150U/L, LDH >250U/L. CONCLUSION: This systematic review suggests that COVID-19 is a disease with varied clinical presentation and laboratory parameters. The commonest clinical symptoms were fever, cough and dyspnea. The laboratory parameters associated with severe disease were lymphopenia, elevated LDH, D dimer and Procalcitonin.


Asunto(s)
Aspartato Aminotransferasas/sangre , COVID-19/sangre , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , L-Lactato Deshidrogenasa/sangre , Leucocitosis/sangre , Linfopenia/sangre , Polipéptido alfa Relacionado con Calcitonina/sangre , Trombocitopenia/sangre , COVID-19/epidemiología , COVID-19/fisiopatología , Comorbilidad , Tos/fisiopatología , Disnea/fisiopatología , Fiebre/fisiopatología , Humanos , Respiración Artificial , Factores de Riesgo , SARS-CoV-2 , Índice de Severidad de la Enfermedad
10.
Am J Infect Control ; 49(1): 82-89, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32540370

RESUMEN

OBJECTIVE: We aimed to investigate the relationship between clinical characteristics, outcomes and the severity of severe acute respiratory syndrome coronavirus 2 pneumonia. METHODS: We performed a systematic review and meta-analysis using PubMed, Embase, and Cochrane Library databases to assess the clinical characteristics and outcomes of confirmed COVID-19 cases and compared severe (ICU) and nonsevere (non-ICU) groups. RESULTS: We included 12 cohort studies including 2,445 patients with COVID-19. Compared with nonsevere (non-ICU) patients, severe (ICU) disease was associated with a smoking history (P = .003) and comorbidities including chronic obstructive pulmonary disease (OR = 5.08, P < .001), diabetes (OR = 3.17, P < .001), hypertension (OR = 2.40, P < .001), coronary heart disease (OR = 2.66, P < .001), cerebrovascular diseases (OR = 2.68, P = .008), and malignancy (OR=2.21, P = .040). We found significant differences between the 2 groups for fever, dyspnea, decreased lymphocyte and platelet counts, and increased leukocyte count, C-creative protein, procalcitonin, lactose dehydrogenase, aspartate aminotransferase, alanine aminotransferase, creatinine kinase, and creatinine levels (P < .05). Significant differences were also observed for multiple treatments (P < .05). Patients in the severe (ICU) group were more likely to have complications and had a much higher mortality rate and lower discharge rate than those with nonsevere (non-ICU) disease (P < .05). CONCLUSIONS: Investigation of clinical characteristics and outcomes of severe cases of COVID-19 will contribute to early prediction, accurate diagnosis, and treatment to improve the prognosis of patients with severe illness.


Asunto(s)
COVID-19/fisiopatología , Disnea/fisiopatología , Fiebre/fisiopatología , Leucocitosis/fisiopatología , Linfopenia/fisiopatología , Trombocitopenia/fisiopatología , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Proteína C-Reactiva/metabolismo , COVID-19/sangre , COVID-19/mortalidad , Trastornos Cerebrovasculares/epidemiología , Comorbilidad , Enfermedad Coronaria/epidemiología , Creatina Quinasa/sangre , Creatinina/sangre , Diabetes Mellitus/epidemiología , Humanos , Hipertensión/epidemiología , Unidades de Cuidados Intensivos , L-Lactato Deshidrogenasa/sangre , Leucocitosis/sangre , Linfopenia/sangre , Polipéptido alfa Relacionado con Calcitonina/sangre , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Fumar/epidemiología , Trombocitopenia/sangre
11.
Eur J Clin Invest ; 51(1): e13404, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32918295

RESUMEN

BACKGROUND: The clinical presentation of COVID-19 ranges from a mild, self-limiting disease, to multiple organ failure and death. Most severe COVID-19 cases present low lymphocytes counts and high leukocytes counts, and accumulated evidence suggests that in a subgroup of patients presenting severe COVID-19, there may be a hyperinflammatory response driving a severe hypercytokinaemia which may be, at least in part, signalling the presence of an underlying endothelial dysfunction. In this context, available data suggest a prognostic role of neutrophil-lymphocyte ratio (NLR) in various inflammatory diseases and oncological processes. Following this rationale, we hypothesized that NLR, as a marker of endothelial dysfunction, may be useful in identifying patients with a poor prognosis in hospitalized COVID-19 cases. DESIGN: A retrospective observational study performed at Hospital Universitario HM Puerta del Sur, Madrid, Spain, which included 119 patients with COVID-19 from 1 March to 31 March 2020. Patients were categorized according to WHO R&D Expert Group. RESULTS: Forty-five (12.1%) patients experienced severe acute respiratory failure requiring respiratory support. Forty-seven (12.6%) patients died. Those with worse outcomes were older (P = .002) and presented significantly higher NLR at admission (P = .001), greater increase in Peak NLR (P < .001) and higher increasing speed of NLR (P = .003) compared with follow-up patients. In a multivariable logistic regression, age, cardiovascular disease and C-reactive protein at admission and Peak NLR were significantly associated with death. CONCLUSIONS: NLR is an easily measurable, available, cost-effective and reliable parameter, which continuous monitoring could be useful for the diagnosis and treatment of COVID-19.


Asunto(s)
COVID-19/sangre , Mortalidad Hospitalaria , Leucocitosis/sangre , Linfocitos , Linfopenia/sangre , Neutrófilos , Factores de Edad , Anciano , Anciano de 80 o más Años , Proteína C-Reactiva/inmunología , COVID-19/inmunología , COVID-19/mortalidad , Enfermedades Cardiovasculares/epidemiología , Comorbilidad , Diabetes Mellitus/epidemiología , Endotelio Vascular/fisiopatología , Femenino , Humanos , Hipertensión/epidemiología , L-Lactato Deshidrogenasa/sangre , Recuento de Leucocitos , Leucocitosis/inmunología , Modelos Logísticos , Recuento de Linfocitos , Linfopenia/inmunología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Estudios Retrospectivos , SARS-CoV-2 , Índice de Severidad de la Enfermedad , España/epidemiología
12.
Hematology ; 25(1): 507-514, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33317436

RESUMEN

OBJECTIVES: Hyperleukocytosis (HL) is a laboratory abnormality commonly presented in patients with acute myeloid leukemia (AML). However, large cohort studies on the clinical significance of HL in pediatric AML are paucity. Moreover, the effect of stem cell transplantation in HL patients remains unknown. METHODS: The clinical profiles of 885 pediatric patients with AML were downloaded from the TARGET dataset. HL was defined as an initial peripheral WBC count of ≥ 100 ×109/L. We analyzed the prevalence, clinical profile and prognosis of HL in these patients. RESULTS: The frequency of HL among all the pediatric AML was 22.6%. FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation and gene fusion of NUP98/NSD1 occurred with higher incidence in HL patients. Overall, HL was associated with a low induction complete remission rate, and high risk of induction death. Moreover, HL predicted a significantly inferior 5-year event-free survival (EFS) (P < 0.001) and a trend of inferior 5-year overall survival (OS) (P = 0.059). However, compared with chemotherapy, stem cell transplantation had no significant effect on the survival of HL patients in terms of 5-year leukemia-free survival (P = 0.449) or OS (P = 0.447). Multivariate analysis revealed that HL was an independent prognosis factor for EFS (Hazard ratio:1.352, P = 0.013) but not for OS (Hazard ratio:1.225, P = 0.170) in pediatric AML. CONCLUSION: HL might predict inferior clinical outcome in pediatric AML. SCT is an effective therapy for AML, but it may have no better effect on the survival of patients with HL, compared to chemotherapy.


Asunto(s)
Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/mortalidad , Recuento de Leucocitos , Leucocitosis/sangre , Factores de Edad , Niño , Terapia Combinada , Bases de Datos Factuales , Humanos , Leucemia Mieloide Aguda/epidemiología , Leucemia Mieloide Aguda/patología , Leucocitosis/patología , Evaluación del Resultado de la Atención al Paciente , Prevalencia , Pronóstico
13.
Eur Rev Med Pharmacol Sci ; 24(24): 13065-13071, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33378060

RESUMEN

OBJECTIVE: Whether patients with COVID-19 require invasive mechanical ventilation (MV) is not yet clear. This article summarizes the clinical treatment process and clinical data of patients with COVID-19 and analyzes the predictive factors for mechanical ventilation for these patients. MATERIALS AND METHODS: A retrospective study was carried out from January 5, 2020, to March 23, 2020, including 98 patients with COVID-19 treated at three designated hospitals in Huangshi City, Hubei Province. Data collection included demographics, previous underlying diseases, clinical manifestations, laboratory examinations, imaging examination results, diagnosis, and prognosis. This study presents a summary of the patients' overall clinical characteristics and clarifies the predictive factors for MV in patients with COVID-19. RESULTS: There were 56 males and 42 females included in this study. The mortality rate was 26.53% (26/98). Fever, cough, and chest tightness were the most common symptoms (64.3%, 37.8%, and 12.2%, respectively). Thirty cases required MV, 30.61% of the total cases, and the mortality rate was 73.33%. The univariate comparison showed that dyspnea, acute physiologic assessment, chronic health evaluation (APACHE II) score, and the ratio between arterial blood oxygen partial pressure (PaO2) and oxygen concentration (FiO2) (P/F) were statistically different between the MV group and the non-MV group (p < 0.05). CONCLUSIONS: Results showed the following: dyspnea; increased white blood cell count; decreased platelets; lowered albumin levels; increased urea nitrogen; increased levels of myocardial enzymes Creatine Kinase (CK), Creatine Kinase, MB Form (CKMB) and lactate dehydrogenase (LDH); increased lactate, and lowered blood calcium tests. These findings may indicate that the patients have an increased probability of needing MV support. A cutoff value for the initial APACHE II score of >11.5 and the initial PaO2/FiO2 ratio of <122.17 mmHg should be considered for MV support for patients with COVID-19.


Asunto(s)
COVID-19/terapia , Oxígeno/sangre , Presión Parcial , Respiración Artificial/estadística & datos numéricos , APACHE , Anciano , Anciano de 80 o más Años , Área Bajo la Curva , Nitrógeno de la Urea Sanguínea , COVID-19/sangre , COVID-19/mortalidad , COVID-19/fisiopatología , Creatina Quinasa/sangre , Forma MB de la Creatina-Quinasa/sangre , Disnea/fisiopatología , Femenino , Humanos , Hipoalbuminemia/sangre , Hipocalcemia/sangre , L-Lactato Deshidrogenasa/sangre , Ácido Láctico/sangre , Leucocitosis/sangre , Masculino , Persona de Mediana Edad , Curva ROC , Estudios Retrospectivos , Medición de Riesgo , SARS-CoV-2 , Trombocitopenia/sangre
14.
Eur Rev Med Pharmacol Sci ; 24(22): 11926-11933, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33275265

RESUMEN

OBJECTIVE: Hematologic cancer patients with Coronavirus Disease 2019 (COVID-19) tend to have a more serious disease course than observed in the general population. Herein, we comprehensively reviewed existing literature and analyzed clinical characteristics and mortality of patients with hematologic malignancies and COVID-19. MATERIALS AND METHODS: Through searching PubMed until June 03, 2020, we identified 16 relevant case studies (33 cases) from a total of 45 studies that have reported on patients with COVID-19 and hematologic malignancies. We investigated the clinical and laboratory characteristics including type of hematologic malignancies, initial symptoms, laboratory findings, and clinical outcomes. Then, we compared those characteristics and outcomes of patients with hematologic malignancies and COVID-19 to the general population infected with COVID-19. RESULTS: The median age was 66-year-old. Chronic lymphocytic leukemia was the most common type of hematologic malignancy (39.4%). Fever was the most common symptom (75.9%). Most patients had normal leukocyte counts (55.6%), lymphocytosis (45.4%), and normal platelet counts (68.8%). In comparison to patients with COVID-19 without underlying hematologic malignancies, dyspnea was more prevalent (45.0 vs. 24.9%, p=0.025). Leukocytosis (38.9 vs. 9.8%, p=0.001), lymphocytosis (45.4 vs. 8.2%, p=0.001), and thrombocytopenia (31.3 vs. 11.4%, p=0.036) were significantly more prevalent and lymphopenia (18.2 vs. 57.4%, p=0.012) less prevalent in patients with hematologic malignancies. There were no clinical and laboratory characteristics predicting mortality in patients with hematologic malignancies. Mortality was much higher in patients with hematologic malignancies compared to those without this condition (40.0 vs. 3.6%, p<0.001). CONCLUSIONS: Co-occurrence of hematologic malignancies and COVID-19 is rare. However, due to the high mortality rate from COVID-19 in this vulnerable population, further investigation on tailored treatment and management is required.


Asunto(s)
COVID-19/complicaciones , Disnea/fisiopatología , Neoplasias Hematológicas/complicaciones , Linfocitosis/sangre , Linfopenia/sangre , Trombocitopenia/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/sangre , COVID-19/mortalidad , COVID-19/fisiopatología , Niño , Preescolar , Disnea/epidemiología , Femenino , Fiebre/epidemiología , Fiebre/fisiopatología , Humanos , Leucemia Linfocítica Crónica de Células B/complicaciones , Leucocitosis/sangre , Leucocitosis/epidemiología , Linfocitosis/epidemiología , Linfoma no Hodgkin/complicaciones , Linfopenia/epidemiología , Masculino , Persona de Mediana Edad , Mieloma Múltiple/complicaciones , Trombocitopenia/epidemiología , Adulto Joven
15.
Monaldi Arch Chest Dis ; 90(4)2020 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-33169598

RESUMEN

COVID-19 is a pandemic with over 5 million cases worldwide. The disease has imposed a huge burden on health resources. Evaluation of clinical and epidemiological profiles of such patients can help in understanding and managing the outbreak more efficiently. This study was a prospective observational analysis of 200 diagnosed COVID-19 patients admitted to a tertiary care center from 20th march to 8th May 2020. All these patients were positive for COVID-19 by an oro-nasopharyngeal swab-rtPCR based testing. Analyses of demographic factors, clinical characteristics, comorbidities, laboratory parameters, and the outcomes were performed. The mean age of the population was 40 years with a slight male predominance (116 patients out of 200, 58%). A majority of the patients (147, 73.5 %) were symptomatic, with fever being the most common symptom (109, 54.5%), followed by cough (91, 45.5%). An older age, presence of symptoms and their duration, leukocytosis, a high quick SOFA score, a high modified SOFA score, need for ventilator support, an AST level more than 3 times the upper limit of normal (ULN), and a serum creatinine level of 2 mg/dl or greater were at a significantly higher risk of ICU admission and mortality. Presence of diabetes mellitus, AST > three times ULN, serum creatinine 2 mg/dl or higher, and a qSOFA score of 1 or higher were all associated with significantly greater odds of critical care requirement. Triage and severity assessment helps in deciding the requirement for a hospital stay and ICU admission for COVID-19 which can easily be done using clinical and laboratory parameters. A mild, moderate and severe category approach with defined criteria and treatment guidelines will help in judicious utilization of health-care resources, especially for developing countries like India.   *Other members of the Safdarjung Hospital COVID-19 working group: Balvinder Singh (Microbiology), MK Sen (Pulmonary Medicine), Shibdas Chakrabarti (Pulmonary Medicine), NK Gupta (Pulmonary medicine), AJ Mahendran (Pulmonary Medicine), Ramesh Meena (Medicine), G Usha (Anaesthesiology), Santvana Kohli (Anaesthesiology), Sahil Diwan (Anaesthesiology), Rushika Saksena (Microbiology), Vikramjeet Dutta (Microbiology), Anupam Kr Anveshi (Microbiology).


Asunto(s)
Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/fisiopatología , Neumonía Viral/sangre , Neumonía Viral/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alanina Transaminasa/sangre , Anemia/sangre , Aspartato Aminotransferasas/sangre , Betacoronavirus , COVID-19 , Niño , Preescolar , Comorbilidad , Enfermedad de la Arteria Coronaria/epidemiología , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/terapia , Tos/fisiopatología , Creatinina/sangre , Diabetes Mellitus/epidemiología , Femenino , Fiebre/fisiopatología , Humanos , Hipertensión/epidemiología , Hipoxia/fisiopatología , India/epidemiología , Lactante , Recién Nacido , Unidades de Cuidados Intensivos , Tiempo de Internación , Recuento de Leucocitos , Leucocitosis/sangre , Linfopenia/sangre , Linfopenia/fisiopatología , Masculino , Persona de Mediana Edad , Mialgia/fisiopatología , Puntuaciones en la Disfunción de Órganos , Pandemias , Faringitis/fisiopatología , Recuento de Plaquetas , Neumonía Viral/mortalidad , Neumonía Viral/terapia , Estudios Prospectivos , Respiración Artificial , SARS-CoV-2 , Taquipnea/fisiopatología , Centros de Atención Terciaria , Factores de Tiempo , Tuberculosis/epidemiología , Adulto Joven
16.
Bull Exp Biol Med ; 169(6): 795-797, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33098506

RESUMEN

The effects of TLR4 blocker on blood cell morphology, concentrations proinflammatory cytokines, and functional state of the liver and kidneys were studied in outbred male rats (n=60) after intravenous injection of 20 mg/kg LPS isolated from opportunistic Proteus mirabilis strain ATCC 51393. TLR4 blocker TLR4-IN-C34 was injected intravenously in a dose of 1 mg/kg/day over 3 days. Systemic inflammatory reaction induced by LPS was characterized by elevation of serum TNFα, IL-1ß, IL-6, erythrocyte sedimentation rate, leukocytosis, and thrombocytosis. Increased activity of hepatocyte enzymes (ALT, alkaline phosphatase, and lactate dehydrogenase), retention of nitrogen metabolites (urea and creatinine), elevated content of protein oxidation products, and enhanced protein catabolism were also observed. Administration of TLR4 blocker reduced parameters of inflammatory reaction and prevented the development of hypercatabolic syndrome; endotoxicosis and kidney function indicators approached the normal levels.


Asunto(s)
Antiinflamatorios/farmacología , Leucocitosis/tratamiento farmacológico , Lipopolisacáridos/antagonistas & inhibidores , Piranos/farmacología , Sepsis/tratamiento farmacológico , Trombocitosis/tratamiento farmacológico , Receptor Toll-Like 4/antagonistas & inhibidores , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Animales , Animales no Consanguíneos , Creatinina/sangre , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Inyecciones Intravenosas , Interleucina-1beta/sangre , Interleucina-1beta/genética , Interleucina-6/sangre , Interleucina-6/genética , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , L-Lactato Deshidrogenasa/sangre , Leucocitosis/sangre , Leucocitosis/patología , Lipopolisacáridos/toxicidad , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Proteus mirabilis/química , Ratas , Sepsis/sangre , Sepsis/patología , Transducción de Señal , Trombocitosis/sangre , Trombocitosis/patología , Receptor Toll-Like 4/sangre , Receptor Toll-Like 4/genética , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/genética , Urea/sangre
17.
Geriatr Gerontol Int ; 20(10): 951-955, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32876981

RESUMEN

AIM: Although various neutrophilic immunosenescence mechanisms have been shown, there are few clinical studies on age-related differences in leukocytosis against acute bacterial infections, including acute colonic diverticulitis. METHODS: We performed a retrospective study of 26 patients ≥65 years old and 211 patients 16-64 years old who were hospitalized for acute colonic diverticulitis at Toho University Medical Center Omori Hospital between 2010 and 2016. We compared patients' characteristics, including sex, immunocompromised status, diverticulitis site, complications, severity, previous diverticulitis, vital signs, leukocyte counts, neutrophil-to-lymphocyte ratio and serum C-reactive protein on admission. To adjust for confounding factors, we performed a logistic regression analysis. RESULTS: Univariate comparisons showed that leukocyte count (older: 10 850 [interquartile range, 9400-12 000]/mm3 vs. younger: 12 600 [interquartile range, 10 500-15 000]/mm3 , P = 0.004) and prevalence of leukocytosis (leukocytes >11 000/mm3 ) were lower in older compared with younger patients. There were significantly more female, left-sided diverticulitis and immunocompromised patients in the older compared with the younger group. Logistic regression showed that leukocyte count, prevalence of female patients, and left-sided diverticulitis were independent predictors for the older patients: Their odds ratios were 0.866 (95% confidence interval [95% CI] 0.753-0.996), 2.631 (95% CI, 1.032-6.707) and 5.810 (95% CI, 2.328-14.497), respectively. CONCLUSION: Caution should be taken when managing older patients with colonic diverticulitis because reactive leukocytosis might be poor, possibly reflecting immunosenescence. Geriatr Gerontol Int 2020; 20: 951-955.


Asunto(s)
Diverticulitis del Colon/epidemiología , Leucocitosis/epidemiología , Enfermedad Aguda , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Diverticulitis del Colon/sangre , Femenino , Humanos , Inmunosenescencia , Japón , Recuento de Leucocitos , Leucocitosis/sangre , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Estudios Retrospectivos , Adulto Joven
18.
Cells ; 9(10)2020 09 25.
Artículo en Inglés | MEDLINE | ID: mdl-32992967

RESUMEN

To investigate whether and how cerebrospinal fluid (CSF) findings can contribute to distinguish tick-borne encephalitis (TBE) from herpes simplex virus (HSV) and varicella zoster virus (VZV) induced central nervous system (CNS) infections (HSV-I, VZV-I). Chart review and identification of TBE, HSV- I, and VZV-I was carried out, fulfilling the following criteria: (1) clinical signs of encephalitis and/or meningitis, (2) complete CSF analysis and confirmed viral etiology by either PCR or antibody testing in CSF, (3) hospitalized patients, and (4) available brain magnetic resonance imaging (MRI). Fifty-nine patients with 118 CSF/serum pairs were included. These comprised 21 with TBE (35 CSF/serum pairs), 20 (40 CSF/serum pairs) with HSV-I, and 18 (43 CSF/serum pairs) with VZV-I. In contrast to HSV-I and VZV-I, CSF cell differentiation in TBE showed more often an increased (>20%) proportion of granulocytes (p < 0.01) and a more frequent quantitative intrathecal IgM synthesis (p = 0.001 and p < 0.01, respectively), while the second was even more pronounced when follow-up CSF analyses were included (p < 0.001). CSF findings help to distinguish TBE from other viral infections. In cases with CSF pleocytosis and a positive history for a stay in or near an endemic area, TBE antibodies in CSF and serum should be determined, especially if granulocytes in CSF cell differentiation and/or an intrathecal IgM synthesis is present.


Asunto(s)
Infecciones del Sistema Nervioso Central/diagnóstico , Diagnóstico Diferencial , Encefalitis Transmitida por Garrapatas/diagnóstico , Meningitis/diagnóstico , Adulto , Anciano , Infecciones del Sistema Nervioso Central/sangre , Infecciones del Sistema Nervioso Central/líquido cefalorraquídeo , Infecciones del Sistema Nervioso Central/virología , Encefalitis Transmitida por Garrapatas/sangre , Encefalitis Transmitida por Garrapatas/líquido cefalorraquídeo , Encefalitis Transmitida por Garrapatas/virología , Femenino , Herpesvirus Humano 3/patogenicidad , Humanos , Inmunidad Humoral/genética , Inmunidad Humoral/inmunología , Inmunoglobulina M/sangre , Leucocitosis/sangre , Leucocitosis/líquido cefalorraquídeo , Leucocitosis/diagnóstico , Leucocitosis/virología , Imagen por Resonancia Magnética , Masculino , Meningitis/sangre , Meningitis/líquido cefalorraquídeo , Meningitis/virología , Persona de Mediana Edad , Simplexvirus/inmunología , Simplexvirus/patogenicidad
19.
Int J Infect Dis ; 100: 199-206, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32920230

RESUMEN

OBJECTIVES: Tuberculosis (TB) is the leading infectious cause of death in the world. Cheaper and more accessible TB treatment monitoring methods are needed. Here, we evaluated white blood cell (WBC) absolute counts, lymphocyte, and monocyte proportions during TB treatment, and characterized their association with treatment failure. METHODS: This multicentered prospective cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included and followed up after two months of treatment and at the end of therapy. Blood counts were compared to treatment outcome using descriptive statistics, logistic regression, and Receiver Operating Characteristic (ROC) analyses. RESULTS: Between December 2017 and August 2020, 198 participants were enrolled, and 152 completed treatment, including 28 (18.5%) drug-resistant patients. The rate of cure at the end of treatment was 90.8% (138/152). WBC absolute counts decreased, and lymphocyte proportions increased throughout treatment. In multivariate analyses, baseline high WBC counts and low lymphocyte proportions were associated with positive sputum culture results at the end of treatment (WBC > 11,450 cells/mm3: p = 0.048; lymphocytes <16.0%: p = 0.039; WBC > 11,450 cells/mm3 and lymphocytes <16.0%: p = 0.024). CONCLUSION: High WBC counts and low lymphocyte proportions at baseline are significantly associated with the risk of TB treatment failure.


Asunto(s)
Leucocitosis/sangre , Linfocitos , Linfopenia/sangre , Monocitos , Tuberculosis Pulmonar/tratamiento farmacológico , Adulto , Bangladesh , Estudios de Cohortes , Femenino , Georgia , Humanos , Líbano , Recuento de Leucocitos , Madagascar , Masculino , Persona de Mediana Edad , Paraguay , Estudios Prospectivos , Esputo/microbiología , Insuficiencia del Tratamiento , Tuberculosis Pulmonar/sangre , Tuberculosis Pulmonar/microbiología , Adulto Joven
20.
Transfusion ; 60(10): 2360-2369, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32776542

RESUMEN

BACKGROUND: Up to 20% of patients with acute myeloid leukemia (AML) present with hyperleukocytosis, usually defined as a white blood cell (WBC) count greater than 100 × 109 /L. Given the high early mortality rate, emergent cytoreduction with either leukapheresis, hydroxyurea, or chemotherapy is indicated, but the optimal strategy is unknown. STUDY DESIGN AND METHODS: For this systematic review and meta-analysis we searched MEDLINE and EMBASE via Ovid, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from inception through March 2020 for multiarm studies comparing early mortality rates of patients with AML treated with leukapheresis and those who were not. The risk ratio (RR) of early death for patients who received leukapheresis vs patients who did not was estimated using a sum of the log-ratio of individual study estimates weighted by sample size. RESULTS: Among 13 two-arm, retrospective studies with 1743 patients (486 leukapheresis and 1257 nonleukapheresis patients), leukapheresis did not improve the primary outcome of early mortality compared to treatment strategies in which leukapheresis was not used (RR, 0.88; 95% confidence interval [CI], 0.69-1.13; P = .321) without statistically significant heterogeneity between studies (Cochran's Q, 18; P = .115; I2 , 33.4%). Patients presenting with clinical leukostasis tended to be more likely to undergo leukapheresis (odds ratio, 2.01; 95% CI, 0.99-4.08; P = .052). CONCLUSION: As we did not find evidence of a short-term mortality benefit and considering the associated complications and logistic burden, our results argue against the routine use of leukapheresis for hyperleukocytosis among patients with AML.


Asunto(s)
Hidroxiurea/uso terapéutico , Leucaféresis , Leucemia Mieloide Aguda , Leucocitosis , Supervivencia sin Enfermedad , Humanos , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/terapia , Leucocitosis/sangre , Leucocitosis/mortalidad , Leucocitosis/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...